SUNPHARMA Q2 FY27 Results & Concall Summary: Key Takeaways (SUNPHARMA)

SUNPHARMA Q2 FY27 (Sep-2026 Qtr) Earnings call highlights: Key takeaways, performance, financial metrics, outlook and guidance, concerns and management tone.

  • SUNPHARMA Financials
  • SUNPHARMA Shareholding Pattern
  • SUNPHARMA Earnings Documents
  • SUNPHARMA Announcements
  • SUNPHARMA Corporate Actions
  • SUNPHARMA Bulk, Block & Insider Deals
  • SUNPHARMA Delivery Data
  • SUNPHARMA Earnings Concalls
  • Market Timeline
  • Concall Monitor
  • Company Research
  • Earnings Monitor
  • Upcoming Results
  • Sector Monitor
  • Sector Performance
  • Bulk & Block Deals
  • Delivery Data
  • FII & DII Activity
  • Market Indices
  • Plans & Pricing

Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q2FY27 Concall Summary - Sep-2026 Qtr

Key Takeaways

  • Management is implementing corrective measures to address a slowdown in US Ilumya sales, expecting a return to growth aided by the new psoriatic arthritis indication.
  • The company reaffirmed its full-year guidance of high single-digit revenue growth despite a strong first-half performance, suggesting a more moderate outlook for the second half.
  • R&D spending, currently at 4.8% of sales, is expected to significantly ramp up in H2 to meet the full-year guidance of 6-7% of sales.

Performance Overview

  • Delivered strong consolidated sales growth of 11.8% in Q2 FY27, driven by robust performance in the India business.
  • The India formulations business recorded a significant 17.3% growth, outperforming the Indian Pharmaceutical Market (IPM).
  • US business experienced an 8.2% year-over-year decline due to lenalidomide erosion, although it grew 6.5% sequentially.
  • Global Innovative Medicine sales increased by 6.9%, but a slowdown in the US Ilumya business was a notable headwind.
  • The planned acquisition of Organon is progressing on schedule, with the transaction expected to close in Q4 of FY27.

Financial Metrics

Log in to Stocksigma to read the Financial Metrics section of this summary.

Operating Performance / Business Segments

Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.

Key Discussions & Insights

Log in to Stocksigma to read the Key Discussions & Insights section of this summary.

Outlook and Guidance

Log in to Stocksigma to read the Outlook and Guidance section of this summary.

Challenges / Concerns

Log in to Stocksigma to read the Challenges / Concerns section of this summary.

Industry / Competitive Landscape

Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.

Overall Summary

Log in to Stocksigma to read the Overall Summary section of this summary.

Tone & Disclosure

Log in to Stocksigma to read the Tone & Disclosure section of this summary.

  • SUNPHARMA Q2FY27 Concall Transcript
  • SUNPHARMA Q2FY27 Management Mirror
  • SUNPHARMA Q1FY27 Concall Summary (Jun-2026 Qtr)